Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors

What Was Tested

This randomized controlled trial paper looks at Glucagon.

The researchers report the effects of everolimus on gastrin and glucagon levels in patients with progressive pNET in RADIANT-1 (a single-arm phase II trial) and RADIANT-3 (a placebo-controlled, randomized, phase III trial).

Who Took Part

According to the abstract, 158 patients were involved.

The age groups tagged for this paper are young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Serum gastrin and glucagon levels were determined by immunoassay at baseline and at predose in subsequent treatment cycles in patients with elevated baseline hormone levels.

The analyses included 158 patients from RADIANT-1 and 404 patients from RADIANT-3.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Antineoplastic Agents, Biomarkers, Tumor, Disease-Free Survival, Down-Regulation, Everolimus, Gastrins and Glucagon.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 158 patients.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Pancreas), a journal based in United States.

More context: the Glucagon compound page, all human trials.